Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation

Cromm, Philipp M., Samarasinghe, Kusal T. G., Hines, John, Crews, Craig M.·2018·Journal of the American Chemical Society
DOI 10.1021/jacs.8b08008

Cited by (311)

Items 101–200 of 311

  1. Aminopyrimidines: Recent synthetic procedures and anticancer activities
    Éclair Venturini Filho, Erick M.C. Pinheiro, Sérgio Pinheiro, Sandro J. Greco · 2021 · Tetrahedron
  2. Focal adhesion kinase signaling – tumor vulnerabilities and clinical opportunities
    David D. Schlaepfer, Marjaana Ojalill, Dwayne G. Stupack · 2024 · Journal of Cell Science
  3. The therapeutic potential of PROTACs
    Andrew B. Benowitz, Katherine L. Jones, John D. Harling · 2020 · Expert Opinion on Therapeutic Patents
  4. Target Validation Using PROTACs: Applying the Four Pillars Framework
    Radosław P. Nowak, Lyn H. Jones · 2020 · SLAS DISCOVERY
  5. New Insights on the Nuclear Functions and Targeting of FAK in Cancer
    Silvia Pomella, Matteo Cassandri, Maria Rita Braghini, Francesco Marampon, Anna Alisi, Rossella Rota · 2022 · International Journal of Molecular Sciences
  6. A Temporal PROTAC Cocktail‐Mediated Sequential Degradation of AURKA Abrogates Acute Myeloid Leukemia Stem Cells
    Fang Liu, Xuan Wang, Jianli Duan, Zhijie Hou, Zhouming Wu, Lingling Liu, Hanqi Lei, Dan Yang Huang, Yifei Ren, Yue Wang et al. · 2022 · Advanced Science
  7. PROTACS: A technology with a gold rush-like atmosphere
    Yuwei Wang, Li Lan, Min Wang, Jinyang Zhang, Yuhui Gao, Lei Shi, Li‐Ping Sun · 2022 · European Journal of Medicinal Chemistry
  8. The application of PROTAC in HDAC
    Shaoting Chen, Yuxiang Zheng, Benji Liang, Yudong Yin, Jian Yao, Quande Wang, Yanghan Liu, Nouri Neamati · 2023 · European Journal of Medicinal Chemistry
  9. Induced proximity-based therapeutic modalities
    Elizabeth A. King, Margot Meyers, Daniel K. Nomura · 2025 · Nature Reviews Drug Discovery
  10. The treatment landscape of triple-negative breast cancer
    Yi Hu, Chen Wang, Huishi Liang, Jie Li, Qiong Yang · 2024 · Medical Oncology
  11. Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
    Sandeep Rana, Jayapal Reddy Mallareddy, Sarbjit Singh, Lidia Boghean, Amarnath Natarajan · 2021 · Cancers
  12. Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile
    Chaowei Ren, Ning Sun, Haixia Liu, Ying Kong, Renhong Sun, Xing Qiu, Jinju Chen, Yan Li, Jianshui Zhang, Yuedong Zhou et al. · 2021 · Journal of Medicinal Chemistry
  13. Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2
    Muhammed Shaheer, Ravi Singh, Masilamani Elizabeth Sobhia · 2021 · Journal of Biomolecular Structure and Dynamics
  14. Next steps for targeted protein degradation
    Mackenzie W. Krone, Craig M. Crews · 2024 · Cell chemical biology
  15. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs
    Marı́a Maneiro, Elena De Vita, Daniel Conole, Cyrille S. Kounde, Qisi Zhang, Edward W. Tate · 2021 · Progress in medicinal chemistry
  16. Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers
    Mingxing Hu, Yujue Li, Jiaxuan Li, Haoxuan Zhou, Chengyali Liu, Zi Liu, Youling Gong, Binwu Ying, Yongmei Xie · 2022 · European Journal of Medicinal Chemistry
  17. Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
    Jing Liu, Yunhua Peng, Wenyi Wei · 2021 · Frontiers in Cell and Developmental Biology
  18. The clinical advances of proteolysis targeting chimeras in oncology
    Hao Xie, Junjia Liu, Diego Alem, Jason B. Fleming · 2021 · Exploration of Targeted Anti-tumor Therapy
  19. PROTAC: targeted drug strategy. Principles and limitations
    O. A. Koroleva, Yu. V. Dutikova, A. V. Trubnikov, Fedor A. Zenov, Ekaterina V. Manasova, Alexander Albertovich Shtil, Aleksander V. Kurkin · 2022 · Russian Chemical Bulletin
  20. Scaffold hopping enables direct access to more potent PROTACs with in vivo activity
    George M. Burslem, Daniel P. Bondeson, Craig M. Crews · 2020 · Chemical Communications
  21. Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells
    Yao Liu, Yongqi Zhen, Guan Wang, Gaoxia Yang, Leilei Fu, Bo Liu, Liang Ouyang · 2020 · European Journal of Medicinal Chemistry
  22. Targeting focal adhesion kinase (FAK) in cancer therapy: A recent update on inhibitors and PROTAC degraders
    Xiao Wang, Na Li, Yunhe Liu, Ji Wu, Qiu-Ge Liu, Jin-Bo Niu, Yan Xu, Chen‐Zheng Huang, Sai‐Yang Zhang, Jian Song · 2024 · European Journal of Medicinal Chemistry
  23. FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer
    Jinyuan Liu, Lei Xue, Xiang Xu, Jinhua Luo, Shijiang Zhang · 2021 · Experimental Cell Research
  24. Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study
    Yin Sun, Ruifeng Wang, Yu Sun, Lin Wang, Yanli Xue, Jingkai Wang, Tianxiao Wu, Wenbo Yin, Qiaohua Qin, Yixiang Sun et al. · 2022 · European Journal of Medicinal Chemistry
  25. Development and Utility of a PAK1-Selective Degrader
    Hoi-Yee Chow, Sofiia Karchugina, Brian J. Groendyke, Sean T. Toenjes, John M. Hatcher, Katherine A. Donovan, Eric S. Fischer, Gleb Abalakov, Bulat Faezov, Roland L. Dunbrack et al. · 2022 · Journal of Medicinal Chemistry
  26. Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies
    M. Malarvannan, Sujith Unnikrishnan, S. Monohar, V. Ravichandiran, David Paul · 2024 · Bioorganic Chemistry
  27. Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets
    Zonghao Liu, Xiaofang Zhang, Tianru Ben, Mo Li, Yi Jin, Tianlu Wang, Yingqiu Song · 2025 · Biomarker Research
  28. PROTACs technology for targeting non-oncoproteins: Advances and perspectives
    Chao Wang, Yujing Zhang, Dongming Xing, Renshuai Zhang · 2021 · Bioorganic Chemistry
  29. Progress of small molecules for targeted protein degradation: PROTACs and other technologies
    Hongyi Zhao, Minhang Xin, San‐Qi Zhang · 2023 · Drug Development Research
  30. The PEAK family of pseudokinases, their role in cell signalling and cancer
    Onisha Patel, Michael J. Roy, James M. Murphy, Isabelle S. Lucet · 2019 · FEBS Journal
  31. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma
    Alison Kurimchak, Carlos Herrera-Montávez, Jennifer Brown, Katherine J. Johnson, Valerie L. Sodi, Nishi Srivastava, Vikas Kumar, Safoora Deihimi, Shane W. O’Brien, Suraj Peri et al. · 2020 · Science Signaling
  32. PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications
    Narayanaperumal Pravin, Krzysztof Jóźwiak · 2024 · European Journal of Medicinal Chemistry
  33. FAK PROTAC Inhibits Ovarian Tumor Growth and Metastasis by Disrupting Kinase Dependent and Independent Pathways
    Xueyun Huo, Wenjing Zhang, Guannan Zhao, Zhenwen Chen, Peixin Dong, Hidemichi Watari, Ramesh Narayanan, Todd D. Tillmanns, Lawrence M. Pfeffer, Junming Yue · 2022 · Frontiers in Oncology
  34. Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer
    Wei Wei, Zhanzhan Feng, Zhihao Liu, Xinyue Li, Hualong He, Kai Ran, Yaojie Shi, Yongxia Zhu, Tinghong Ye, Chao Gao et al. · 2021 · European Journal of Medicinal Chemistry
  35. Roles of Cullin-RING Ubiquitin Ligases in Cardiovascular Diseases
    Stephanie Diaz, Kankan Wang, Benita Sjögren, Xing Liu · 2022 · Biomolecules
  36. Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling
    Shenxin Zeng, Yuyuan Jin, Heye Xia, Yanwei Shang, Ying‐Zhou Li, Zunyuan Wang, Wenhai Huang · 2023 · Bioorganic Chemistry
  37. New Insights on Fak and Fak Inhibitors
    Chiara Brullo, Bruno Tasso · 2020 · Current Medicinal Chemistry
  38. PROTAC: Novel degradable approach for different targets to treat breast cancer
    Zhenjie Wang, Siyao Che, Zhiqiang Yu · 2024 · European Journal of Pharmaceutical Sciences
  39. The chemical biology of IL-12 production via the non-canonical NFkB pathway
    Peter David Koch, Mikaël J. Pittet, Ralph Weissleder · 2020 · RSC Chemical Biology
  40. Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor
    Brian J. Groendyke, Behnam Nabet, Mikaela L. Mohardt, Haisheng Zhang, Ke Peng, Eriko Koide, Calvin R. Coffey, Jianwei Che, David A. Scott, Adam Joel Bass et al. · 2020 · ACS Medicinal Chemistry Letters
  41. Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs
    Qiaohua Qin, Ruifeng Wang, Qinglin Fu, Guoqi Zhang, Tianxiao Wu, Nian Liu, Ruicheng Lv, Wenbo Yin, Yin Sun, Yixiang Sun et al. · 2022 · Journal of Enzyme Inhibition and Medicinal Chemistry
  42. Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
    Ludovica Lospinoso Severini, Francesca Bufalieri, Paola Infante, Lucia Di Marcotullio · 2022 · Frontiers in Cell and Developmental Biology
  43. Elucidation of genome-wide understudied proteins targeted by PROTAC-induced degradation using interpretable machine learning
    Xie, Li, Xie, Lei · 2023 · PLOS Computational Biology
  44. Development of novel focal adhesion kinase (FAK) inhibitors for targeting cancer: Structural insights and therapeutic potential
    Yingnan Li, Yuming Zhang, Jifa Zhang, Zixuan Zhan, Wuyu Mao · 2024 · European Journal of Medicinal Chemistry
  45. Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy
    Jay Clemens Groppe · 2019 · Expert Opinion on Drug Discovery
  46. Altered Proteostasis in Neurodegenerative Tauopathies
    Katerina Papanikolopoulou, Efthimios M. C. Skoulakis · 2020 · Advances in experimental medicine and biology
  47. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs)
    Daniela Tomaselli, Nicola Mautone, Antonello Mai, Dante Rotili · 2020 · European Journal of Medicinal Chemistry
  48. Methotrexate-based PROTACs as DHFR-specific chemical probes
    Sandeep Rana, Patricia K. Dranchak, Jayme L. Dahlin, Laurence Lamy, Wenqing Li, Erin N. Oliphant, Jonathan H. Shrimp, Girish Halemirle Rajacharya, Ravi Tharakan, David O. Holland et al. · 2023 · Cell chemical biology
  49. Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy
    Yerim Jin, Yeongju Lee · 2024 · ChemMedChem
  50. Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer
    Donatella Romaniello, Alessandra Morselli, Ilaria Marrocco · 2025 · International Journal of Molecular Sciences
  51. FAK Inhibitors As Promising Anticancer Targets: Present and Future Directions
    Muhamad Mustafa, Amer Ali Abd El‐Hafeez, Dalia A Abdelhafeez, Dalia S. Abdelhamid, Yaser A. Mostafa, Pradipta Ghosh, Alaa M. Hayallah, Gamal El‐Din A. Abuo‐Rahma · 2021 · Future Medicinal Chemistry
  52. Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development
    Moyang Lv, Weichao Hu, Shengwei Zhang, Lijiao He, Changjiang Hu, Shiming Yang · 2022 · Cancer Letters
  53. New techniques and strategies in drug discovery (2020–2024 update)
    Qijie Gong, Jian Hua Song, Yihui Song, Kai Tang, Panpan Yang, Xiao Wang, Min Zhao, Liang Ouyang, Li Rao, Bin Yu et al. · 2024 · Chinese Chemical Letters
  54. Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumors
    Jaya Aakriti, Megh Pravin Vithalkar, Swastika Maity, Krishnaprasad Baby, Prabhakara R. Nagareddy, Yogendra Nayak · 2025 · Molecular Biology Reports
  55. Ternary Complex Modeling, Induced Fit Docking and Molecular Dynamics Simulations as a Successful Approach for the Design of VHL‐Mediated PROTACs Targeting the Kinase FLT3
    Husam Nassar, Anne‐Christin Sarnow, Ismail Celik, Mohamed Abdalla M. Abdelsalam, Dina Robaa, Wolfgang Sippl · 2025 · Archiv der Pharmazie
  56. Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer
    Fei Yang, Kangping Xu, Sha Zhang, Jinlin Zhang, Yaoren Qiu, Jin Luo, Guishan Tan, Zhen‐Xing Zou, Wenxuan Wang, Fenghua Kang · 2022 · Bioorganic & Medicinal Chemistry
  57. ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas
    Baishan Jiang, David M. Weinstock, Katherine A. Donovan, Hong-Wei Sun, Ashley Wolfe, Sam Amaka, Nicholas L. Donaldson, Gongwei Wu, Yuan Zhu Jiang, Ryan A. Wilcox et al. · 2023 · Cell chemical biology
  58. Opportunities and challenges for targeting HPK1 in cancer immunotherapy
    Jiamei Xu, Yingzhou Li, Xinyi Chen, Yang Junyi, Heye Xia, Wenhai Huang, Shenxin Zeng · 2024 · Bioorganic Chemistry
  59. Cellular parameters shaping pathways of targeted protein degradation
    Annabel Cardno, Bryony Kennedy, Catherine Lindon · 2025 · Communications Biology
  60. Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity
    Eriko Koide, Mikaela L. Mohardt, Zainab M. Doctor, Annan Yang, Mingfeng Hao, Katherine A. Donovan, Christina C. Kuismi, Alissa J. Nelson, Kathryn Abell, Mike Aguiar et al. · 2023 · ChemBioChem
  61. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
    Qiong Li, Li Zhou, Siyuan Qin, Zhao Huang, Bowen Li, Bowen Li, Mei Yang, Edouard Collins Nice, Huili Zhu, Canhua Huang · 2023 · European Journal of Medicinal Chemistry
  62. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules
    Yuqing Liang, Kutty Selva Nandakumar, Kui Cheng · 2020 · Biochemical Pharmacology
  63. Photoactive Bifunctional Degraders: Precision Tools To Regulate Protein Stability
    Cyrille S. Kounde, Edward W. Tate · 2020 · Journal of Medicinal Chemistry
  64. Chemoproteomics-Enabled De Novo Proteolysis Targeting Chimera Discovery Platform Identifies a Metallothionein Degrader to Probe Its Role in Cancer
    Brittney Racioppo, Dany Pechalrieu, Daniel Abegg, Brendan G. Dwyer, Neal Thomas Ramseier, Ying Hu, Alexander Adibekian · 2025 · Journal of the American Chemical Society
  65. Protein kinases: The key contributors in pathogenesis and treatment of nonalcoholic fatty liver disease-derived hepatocellular carcinoma
    Rong Liu, Mingping Qian, Ying‐Yu Cui · 2023 · Metabolism
  66. A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects
    Ming-shi Xu, Xiao-fan Gu, Cong Li, Lixuan Pan, Zixia Zhu, Meng Fan, Yun Zhao, Jianfang Chen, Xuan Liu, Xiongwen Zhang · 2024 · Acta Pharmacologica Sinica
  67. Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy
    Zhimin Zhang, Liubin Guo, Mengting Zhao, Hao Pan, Dong Zhao, Lingling Wang, Xi Yang, Zhiping Zhang, Mengqiang Wu, Yujie Chang et al. · 2024 · Journal of Medicinal Chemistry
  68. Proteolysis-targeting Chimeras for Targeting Protein for Degradation
    Jianguo Qi, Gang Zhang · 2019 · Future Medicinal Chemistry
  69. Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer
    Pedro Torres‐Ayuso, John Brognard · 2022 · Molecular Pharmacology
  70. In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs)
    Shusuke Tomoshige, Minoru Ishikawa · 2021 · Bioorganic & Medicinal Chemistry
  71. Manipulating autophagic degradation in human diseases: from mechanisms to interventions
    Yiqing Zhang, Xiao-Xia Liu, D. Klionsky, B. Lu, Qing Zhong · 2022 · Life Medicine
  72. Recent advancements in targeted protein knockdown technologies—emerging paradigms for targeted therapy
    Mansi Joshi, Pranay Dey, Abhijit De · 2023 · Exploration of Targeted Anti-tumor Therapy
  73. PROTAC Beyond Cancer- Exploring the New Therapeutic Potential of Proteolysis Targeting Chimeras
    Ritesh P. Bhole, Sapana Patil, Harshad S. Kapare, Rupesh V. Chikhale, Shailendra Shivaji Gurav · 2024 · Current Topics in Medicinal Chemistry
  74. LncRNA FAISL Inhibits Calpain 2‐Mediated Proteolysis of FAK to Promote Progression and Metastasis of Triple Negative Breast Cancer
    Yunmei Zhang, Shiyu Wei, Zhengjie Chen, Rui Xu, Shu‐Rong Li, Lili You, Ruiyue Wu, Yin Zhang, Jian‐You Liao, Xiaoding Xu et al. · 2024 · Advanced Science
  75. Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules
    Alexandré Delport, Raymond Hewer · 2019 · Molecules
  76. Chimera induced protein degradation: PROTACs and beyond
    Lina Yin, Qingzhong Hu · 2020 · European Journal of Medicinal Chemistry
  77. Proteolysis-Targeting Chimeras (PROTACs) Based on Macrocyclic Tetrapeptides Selectively Degrade Class I Histone Deacetylases 1–3
    Martin Roatsch, Anja Vogelmann, Daniel Herp, Manfred Jung, Christian Adam Olsen · 2020 · ChemRxiv
  78. Development of the nonreceptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness
    Yanchun Zhang, Xuexue Xiong, Renhong Sun, Xiaotong Zhu, Chen Wang, Biao Jiang, Xiaobao Yang, Dake Li, Gaofeng Fan · 2023 · Journal of Biological Chemistry
  79. Structure-based discovery of hydrocarbon-stapled paxillin peptides that block FAK scaffolding in cancer
    Lauren Reyes, Lisa Naser, Warren S. Weiner, Darren Thifault, Erik P. Stahl, Liam McCreary, Rohini Nott, Colton Quick, Alex Buchberger, Carlos Alvarado et al. · 2025 · Nature Communications
  80. Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology
    Zere Mukhamejanova, Yichen Tong, Qi Xiang, Fang Xu, Jiyan Pang · 2020 · Current Medicinal Chemistry
  81. Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradation
    Sarah Pogash, Steven Fletcher · 2025 · RSC Medicinal Chemistry
  82. Combinatorial Ubiquitination REal-time PROteolysis (CURE-PROs): A Modular Platform for Generating Reversible, Self-Assembling Bifunctional Targeted Degraders
    Sarah F. Giardina, Elena Valdambrini, Pradeep Kumar Singh, Manny D. Bacolod, Ganesh Babu-Karunakaran, Michael R. Peel, J. David Warren, Francis Barany · 2024 · Journal of Medicinal Chemistry
  83. PROTAC: A Novel Technology for Drug Development**
    Jie Li, Jie‐Qing Liu · 2020 · ChemistrySelect
  84. Expression and purification of functional recombinant CUL2•RBX1 from E. coli
    Stephanie Diaz, Lihong Li, Kankan Wang, Xing Liu · 2021 · Scientific Reports
  85. Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets
    Pedro Torres‐Ayuso, John Brognard · 2019 · Cancers
  86. PROTACting the kinome with covalent warheads
    Deep Rohan Chatterjee, Saumya Kapoor, Meenakshi Jain, Rudradip Das, Moumita Ghosh Chowdhury, Amit Shard · 2022 · Drug Discovery Today
  87. Clinical Progress of Targeted Therapy for Breast Cancer: A Comprehensive Review
    Abhijit Debnath, Rupa Mazumder · 2024 · Current Cancer Drug Targets
  88. Bifunctional robots inducing targeted protein degradation
    Masilamani Elizabeth Sobhia, Harish Kumar, Sonia Kumari · 2023 · European Journal of Medicinal Chemistry
  89. Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets
    Wang, Yungang, Deng, Shouyan, Xu, Jie · 2020 · Cancer Biology and Medicine
  90. Recovery of protein synthesis to assay DNA repair activity in transcribed genes in living cells and tissues
    van der Woude, Melanie, Davó-Martínez, Carlota, Thijssen, Karen L, Vermeulen, Wim, Lans, Hannes · 2023 · Nucleic Acids Research
  91. Chemical degradation of BTK/TEC as a novel approach to inhibit platelet function
    Justin S. Trory, Attila Munkacsi, Kamila M. Śledź, Jordan Vautrinot, Lucy J. Goudswaard, Molly L. Jackson, Kate J. Heesom, Samantha Moore, Alastair W. Poole, Behnam Nabet et al. · 2022 · Blood Advances
  92. Ubiquitin recruiting chimera: more than just a PROTAC
    Tatyana A. Grigoreva, Daria Novikova, Gerry Melino, Nick A. Barlev, Vyacheslav G. Tribulovich · 2024 · Biology Direct
  93. Focal adhesion kinase inhibitors in fibrotic diseases therapy: Development and therapeutic potential.
    Cai-Ling Gan, Wei Wei, Tai-Xiong Xue, Yu-Ting Xie, Lin Yue, Xing-Ping Su, Yan Yu, Zhi-Hao Liu, Ting-Hong Ye · 2025 · European journal of medicinal chemistry
  94. Recent advances in focal adhesion kinase (FAK)-targeting antitumor agents
    Si-Kai Zhu, Qi Wu, Guangxin Liu, Anqi Geng, Pingan Wang · 2025 · RSC Advances
  95. Cryptotanshinone inhibits ovarian tumor growth and metastasis by degrading c-Myc and attenuating the FAK signaling pathway
    Huijun Guo, Wenjing Zhang, Jiaxing Wang, Guannan Zhao, Yaohong Wang, Bing‐Mei Zhu, Peixin Dong, Hidemichi Watari, Baojin Wang, Wěi Li et al. · 2022 · Frontiers in Cell and Developmental Biology
  96. Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues
    Can Zhao, Henian Wang, Wenhu Zhan, Xiaoqing Lv, Xiaodong Ma · 2023 · Journal of Medicinal Chemistry
  97. EGFR degraders in non‐small‐cell lung cancer: Breakthrough and unresolved issue
    Jiayi Shen, Liping Chen, Jihu Liu, Anzhi Li, Lüyin Zheng, Sheng Chen, Yongdong Li · 2024 · Chemical Biology & Drug Design
  98. Dégradation induite des protéines par des molécules PROTAC et stratégies apparentées : développements à visée thérapeutique
    Michèle Reboud‐Ravaux · 2021 · Biologie Aujourd hui
  99. Exploring the Therapeutic Potential of Focal Adhesion Kinase Inhibition in Overcoming Chemoresistance in Pancreatic Ductal Adenocarcinoma
    Fabio Scianò, Francesca Terrana, Camilla Pecoraro, Barbara Parrino, Stella Cascioferro, Patrizia Diana, Elisa Giovannetti, Daniela Carbone · 2024 · Future Medicinal Chemistry
  100. Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective
    Xinrui Yang, Yin He, Richard D. Kim, Jason B. Fleming, Hao Xie · 2020 · Targeted Oncology